New York-based DDB Worldwide has poached Merck & Company’s Singulair anti-asthma drug account from fellow Manhattan agency FCB Worldwide. Spending on the brand is assessed at $40 million.
DDB adds the Singulair business to its existing Merck duties – the arthritis drug Vioxx and a new anti-cholesterol brand marketed jointly with Schering-Plough.
According to Merck, DDB won the business after a four-sided shootout with incumbent FCB and the New York offices of McCann-Erickson Worldwide Advertising and J Walter Thompson.
News source: New York Times
